Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
There are studies that are bound to succeed, and those that are likely to fail. A failed trial is nothing to be proud of – and in this case, it was a gamble against overwhelming odds. We feel the Gilead marketing department was pushing their luck big time with this Continue reading Obeldesivir Fails in Yet Another Study
Let’s just assume that Mr. Martin Shkrely had provided full testimony at the Congressional hearing, this is what it might have said: Read my lips: NO MORE REBATES !
SVR rates in recent DAA combination trials are really impressive. Hardly a month goes by without yet another trial showing excellent efficacy in populations so far considered ‘difficult to treat’, like cirrhotics or post-liver transplant patients on immunosuppressive therapies. This begs the question: is there still room for improvement? Why Continue reading After Harvoni: What’s Still Left to Improve (Besides the Price Tag)?